Acute Exacerbation of CRS Treatment Market is Expected to Reach US$ 7.06 Bn by 2031 – BioSpace

Acute Exacerbation of CRS Treatment Market: Introduction

According to the report, the global acute exacerbation of CRS treatment market was valued over US$ 4.33 Bn in 2020. It is projected to expand at a CAGR of 4.6% from 2021 to 2031. Rhinosinusitis is a major health issue globally. It is an infection of the nasal passages and paranasal sinuses. It has three cardinal symptoms: nasal obstruction, purulent nasal discharge, and facial pain-pressure-fullness. Nasal obstruction is defined by the patient as obstruction, congestion, blockage, or stuffiness; purulent nasal discharge is cloudy or colored in appearance; and facial pain-pressure-fullness involves the anterior face and periorbital region or manifests with headache that can be localized or diffuse.

The rise in cases of rhinosinusitis is expected to drive the acute exacerbation of CRS treatment market during the forecast period. According to the CDC, approximately 28.9 million adults were diagnosed with rhinosinusitis in the U.S. in 2018. Additionally, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the global acute exacerbation of CRS treatment market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82738

Acute Exacerbation of CRS Treatment Market Segmentation

In terms of treatment, the global acute exacerbation of CRS treatment market has been segregated into treatment, route of administration, distribution channel, and infection type. Treatment consists of antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others. The route of administration segment consists of topical, nasal, oral, and injectable. In terms of distribution channel, the global acute exacerbation of CRS treatment market has been split into online pharmacies, retail pharmacies, and hospital pharmacies. Based on infection type, the global acute exacerbation of CRS treatment market has been categorized into staphylococcus species and others.

In terms of treatment, the global acute exacerbation of CRS treatment market has been segmented into antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others. The antibiotics segment dominance is attributed to the high prescription of antibiotics in acute exacerbation of CRS by physicians.

Acute Exacerbation of CRS Treatment Market Drivers

During the projected period, the acute exacerbation of CRS treatment market is anticipated to be driven by an increase in instances of rhinosinusitis. For instance, The prevalence of chronic rhinosinusitis (CRS) worldwide ranges from about 8% in China, 8.4% in Korea, 11% in Europe, and 12% in the U.S. As a result, the worldwide Acute Exacerbation of CRS Treatment market is expected to grow as the number of instances of chronic rhinosinusitis rises.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82738

Regional Segmentation of Acute Exacerbation of CRS Treatment Market

North America dominated the global acute exacerbation of CRS treatment market in 2020, and the trend is anticipated to continue during the forecast period. The U.S. is anticipated to dominate the market in North America during the forecast period, owing to the presence of a large number of key players, high healthcare expenditure, and reimbursement policies favoring the usage of acute exacerbation of CRS treatment in the country.

Surge in healthcare expenditure and rise in awareness about sinusitis are anticipated to fuel the market in Asia Pacific. The market in Asia Pacific is also projected to expand due to robust healthcare expenditure on R&D of pharmaceutical drugs.

The market in Europe is anticipated to be driven by an increase in the demand for drugs for the treatment of acute exacerbation of CRS. Additionally, increase in awareness regarding acute exacerbation of CRS and focus on discovering novel treatment drugs are anticipated to fuel the market in the region.

Competition Landscape

The study also presents profiles of leading players in the global market for acute exacerbation of CRS treatment. These include Sun Pharmaceutical Industries, Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.

Buy Acute Exacerbation of CRS Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=82738&ltype=S

Leading companies in the global market for acute exacerbation of CRS treatment are focused on strengthening the distribution chain and expansion of the product range to gain market share. For instance, on July 26 2020, Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP), for whom therapy with INC does not provide adequate disease control. If approved, omalizumab would be the first treatment for nasal polyps, specifically targeting and blocking immunoglobulin E (IgE), which helps to reduce the size of nasal polyps (as defined by Nasal Polyps Score; NPS) and improve symptoms.

Browse more Reports by Transparency Market Research:

Surgical Sutures Market: The increasing number of surgical cases stands as a key factor boosting the global surgical sutures market. Surgical stitch or suture is a clinical gadget used to hold body tissues together after a physical issue or medical procedure.

Umbilical Cord Blood Banking Market: Some of the key driving factors are complete rights of ownership are with the donor, flexible sites for collection, and secured and assured access to ones cells. Such factors provide significant advantage and glamor to the segment due to which more and more people are getting interested in donating umbilical cord blood in such institutes over public banks.

Cell Expansion Market: The global cell expansion market can be broadly divided into human stem cells, human differentiated cells, and animal cells based on the types of cells. Of them, the human stem cell segment accounts for a leading share in the market vis--vis revenue due of the increasing instances of various chronic diseases and support provided by the government.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read more from the original source:

Acute Exacerbation of CRS Treatment Market is Expected to Reach US$ 7.06 Bn by 2031 - BioSpace